Hypoxia-Inducible Factor-Prolyl-Hydroxylase and Sodium-Glucose Cotransporter 2 Inhibitors for Low-Risk Myelodysplastic Syndrome-Related Anemia in Patients with Chronic Kidney Disease: A Report of Three Cases

被引:2
|
作者
Yamasaki, Satoshi [1 ,2 ,3 ]
Horiuchi, Takahiko [1 ]
机构
[1] Kyushu Univ, Dept Internal Med, Beppu Hosp, Beppu 8740840, Japan
[2] Natl Hosp Org Kyushu Med Ctr, Dept Hematol, Fukuoka 8100065, Japan
[3] Natl Hosp Org Kyushu Med Ctr, Clin Res Inst, Fukuoka 8100065, Japan
关键词
myelodysplastic syndrome; anemia; chronic kidney disease; hypoxia-inducible factor-prolyl-hydroxylase inhibitor; sodium-glucose cotransporter 2 inhibitor; PROGNOSTIC SCORING SYSTEM; CLASSIFICATION;
D O I
10.3390/hematolrep15010019
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Although daprodustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, and dapagliflozin, a sodium-glucose cotransporter 2 inhibitor, have been approved for the treatment of renal anemia in Japan, their efficacy and safety for patients aged 80 years or older with low-risk myelodysplastic syndrome (MDS)-related anemia have not been demonstrated. Our case series comprised two men and one woman aged >80 years with low-risk MDS-related anemia and diabetic mellitus (DM)-related chronic kidney disease who were dependent on red blood cell transfusions and in whom erythropoiesis-stimulating agents had been insufficient. All three patients received daprodustat and additional dapagliflozin achieved red blood cell transfusion independence and were followed up for >6 months. Daily oral daprodustat was well tolerated. There were no fatalities or progression to acute myeloid leukemia during the >6-month follow-up after daprodustat initiation. On the basis of these outcomes, we consider 24 mg of daprodustat combined with 10 mg of dapagliflozin daily an effective form of treatment for low-risk MDS-related anemia. Further studies are required to clarify the synergistic effects of daprodustat and dapagliflozin, which correct chronic kidney disease-related anemia by promoting endogenous erythropoietin production and normalizing iron metabolism to manage low-risk MDS in the long term.
引用
收藏
页码:180 / 187
页数:8
相关论文
共 24 条
  • [1] Hypoxia-inducible factor?prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease
    Haase, Volker H.
    KIDNEY INTERNATIONAL SUPPLEMENTS, 2021, 11 (01) : 8 - 25
  • [2] Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors as a New Treatment Option for Anemia in Chronic Kidney Disease
    Bartnicki, Piotr
    BIOMEDICINES, 2024, 12 (08)
  • [3] Hypoxia-inducible factor prolyl hydroxylase inhibitors: a paradigm shift for treatment of anemia in chronic kidney disease?
    Souza, Ernane
    Cho, Katherine H.
    Harris, Shelby T.
    Flindt, Naomi R.
    Watt, Richard K.
    Pai, Amy Barton
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (08) : 831 - 844
  • [4] Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors for Treatment of Anemia in Chronic Kidney Disease: Guidelines for South Asia
    Abraham, Abi
    Almeida, Alan
    Bhalla, Anil Kumar
    Chaudury, Arpita Ray
    Dutta, Arup Ratan
    Gupta, Ashwani
    Shah, Bharat
    Roy, Biswajeet
    Subbarao, Budithi
    Herath, Chula
    Amrutha, Cynthia
    Shah, Dibya Singh
    Pahari, Dilip Kumar
    Khullar, Dinesh
    Bajpai, Divya
    Simaladinne, Guruvulu Venkata
    Kothari, Jatin
    Tyagi, Jyoti
    Sharma, Inika
    Shah, Kamal
    Malik, Manish
    Sahay, Manisha
    Sharma, Manjuri
    Gumber, Manoj
    Sreelatha, Melemadathil
    Tiwaskar, Mangesh
    Kaur, Manveen
    Alam, Muhammed Rafiqul
    Gopalakrishnan, Natarajan
    Prasad, Narayan
    Kamath, Nivedita
    Meena, Priti
    Varma, Prem Prakash
    Das, Pratik
    Ramachandran, Raja
    Sharma, Raj Kumar
    George, Reena
    Jain, Salil
    Ingale, Samiksha
    Moola, Sandeep
    Bhattacharya, Sandip Kumar
    D'Cruz, Sanjay
    Gulati, Sanjeev
    Saxena, Sanjiv
    Sundar, Sankaran
    Acharya, Shivnarayan
    Bansal, Shyam Bihari
    Vishwanath, Siddini
    Gang, Sishir
    Raju, Sree Bhushan
    INDIAN JOURNAL OF NEPHROLOGY, 2025, 35 (02) : 129 - 167
  • [5] Successful treatment of low-risk myelodysplastic syndrome-related anemia in patients with chronic kidney disease with daprodustat: A report of two cases
    Kunimoto, Hiroyoshi
    Sakuma, Takayuki
    Ohashi, Takuma
    Shirafuta, Mayoko
    Teranaka, Hiroshi
    Nakajima, Hideaki
    EJHAEM, 2024,
  • [6] Future perspectives of anemia management in chronic kidney disease using hypoxia-inducible factor-prolyl hydroxylase inhibitors
    Sugahara, Mai
    Tanaka, Tetsuhiro
    Nangaku, Masaomi
    PHARMACOLOGY & THERAPEUTICS, 2022, 239
  • [7] Iron Supplements Concomitant within Hypoxia-Inducible Factor Prolyl Hydroxylase Domain Inhibitors in the Treatment of Chronic Kidney Disease Anemia
    Wang, Xue
    Wei, Cuiting
    Zhao, Delong
    Sun, Xuefeng
    Zhu, Fengge
    Mei, Yan
    Ma, Qian
    Cai, Guangyan
    Chen, Xiangmei
    Li, Ping
    KIDNEY DISEASES, 2023, 9 (06) : 485 - 497
  • [8] Current treatment practices for anemia in patients with chronic kidney disease and future opportunities with hypoxia-inducible factor prolyl hydroxylase inhibitors: a narrative review
    Kile, Mercedes
    Sudchada, Patcharaporn
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2021, 53 (02) : 283 - 290
  • [9] Current treatment practices for anemia in patients with chronic kidney disease and future opportunities with hypoxia-inducible factor prolyl hydroxylase inhibitors: a narrative review
    Mercedes Kile
    Patcharaporn Sudchada
    International Urology and Nephrology, 2021, 53 : 283 - 290
  • [10] Hypertension Induced by Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in Treating Anemia in Patients With Chronic Kidney Disease: A Mini-Review
    Zhang, Wei
    Li, Yan
    Wang, Ji-Guang
    JOURNAL OF CLINICAL HYPERTENSION, 2024, : 1375 - 1383